PIL - Rosuvastatin 5mg, 10mg, 20mg, 40mg Film-coated Tablets: Change history
View Patient Information Leaflet (PIL - Rosuvastatin 5mg, 10mg, 20mg, 40mg Film-coated Tablets)
Last updated on this site: 16 Sep 2025
SmPC sections 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 for the above-listed MAs have been updated in line with the reference product Crestor 5mg, 10mg, 20mg and 40mg film-coated tablets NL/H/0343/001-004, Grünenthal B.V. Dated Sep 2024. Consequently, the PIL has been updated.
Additionally, SmPC section 6.1 and PIL section 6 have been updated to remove the word ‘anhydrous’ in line with the ninth edition EP.
Date of approval: 08/09/2025
SmPC sections updated: 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 6.1 and 10
Last updated on this site: 16 Sep 2025
SmPC sections 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 for the above-listed MAs have been updated in line with the reference product Crestor 5mg, 10mg, 20mg and 40mg film-coated tablets NL/H/0343/001-004, Grünenthal B.V. Dated Sep 2024. Consequently, the PIL has been updated.
Additionally, SmPC section 6.1 and PIL section 6 have been updated to remove the word ‘anhydrous’ in line with the ninth edition EP.
Date of approval: 08/09/2025
SmPC sections updated: 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 6.1 and 10
-
Changes: (Updated: 16 Sep 2025)
SmPC sections 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 and 5.2 for the above-listed MAs have been updated in line with the reference product Crestor 5mg, 10mg, 20mg and 40mg film-coated tablets NL/H/0343/001-004, Grünenthal B.V. Dated Sep 2024. Consequently, the PIL has been updated.
Additionally, SmPC section 6.1 and PIL section 6 have been updated to remove the word ‘anhydrous’ in line with the ninth edition EP.
Date of approval: 08/09/2025
SmPC sections updated: 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 6.1 and 10
-
Changes: (Updated: 31 Jul 2023)
Description of update: The proposed change is: C.I.2. a) Update SmPC section 4.3 and 4.5 and PIL section 2 and 4 information in line with the information of Reference product (Crestor 5mg, 10mg, 20mg and 40mg filmcoated tablets. The date of approval is 27-July-2023.
PIL sections affected: Title, 1, 2, 3, 4, 6.
-
Changes: (Updated: 02 Jun 2023)
Description of update: To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendation on 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins).
PIL sections updated: 2, 4, 6.
-
Changes: (Updated: 21 Sep 2022)
Initial upload